Peroxynitrite decomposition catalyst reduces vasopressin requirement in ovine MRSA sepsis

[1]  A. Makatsariya,et al.  Septic shock , 2020, Obstetrics, Gynecology and Reproduction.

[2]  Xianzhong Xiao,et al.  [Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis]. , 2019, Zhonghua wei zhong bing ji jiu yi xue.

[3]  M. Singer,et al.  Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis , 2018, Infection.

[4]  K. Kashani,et al.  Management of Refractory Vasodilatory Shock , 2018, Chest.

[5]  A. Kimmoun,et al.  Vasoplegia treatments: the past, the present, and the future , 2018, Critical Care.

[6]  Anna-Maria Burgdorff,et al.  Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms , 2018, The Journal of international medical research.

[7]  Alan E. Jones,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[8]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[9]  D. Prough,et al.  Comparison of Gene Expression by Sheep and Human Blood Stimulated with the TLR4 Agonists Lipopolysaccharide and Monophosphoryl Lipid A , 2015, PloS one.

[10]  C. Vigne,et al.  Norepinephrine: Not too Much, too Long , 2015, Shock.

[11]  T. Vanderah,et al.  Therapeutic potential of peroxynitrite decomposition catalysts: a patent review , 2015, Expert opinion on therapeutic patents.

[12]  J. Angus,et al.  Vasoconstrictor Responses to Vasopressor Agents in Human Pulmonary and Radial Arteries: An In Vitro Study , 2014, Anesthesiology.

[13]  Juanjuan Fan,et al.  The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis* , 2014, Critical care medicine.

[14]  Samuel M Brown,et al.  Survival after shock requiring high-dose vasopressor therapy. , 2013, Chest.

[15]  L. Liaudet,et al.  Role of peroxynitrite in the cardiovascular dysfunction of septic shock. , 2013, Current vascular pharmacology.

[16]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[17]  Matthew Taecker.  Hospitalizations, Costs, and Outcomes of Severe Sepsis in the United States 2003 to 2007 , 2012 .

[18]  T. Lagu,et al.  Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007 , 2012, Critical care medicine.

[19]  H. Ulmer,et al.  Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality , 2011, Intensive Care Medicine.

[20]  C. Sprung,et al.  Characteristics of patients receiving vasopressors. , 2011, Heart & lung : the journal of critical care.

[21]  P. Asfar,et al.  Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside , 2010, Intensive Care Medicine.

[22]  C. Szabó,et al.  PATHOPHYSIOLOGICAL ROLES OF PEROXYNITRITE IN CIRCULATORY SHOCK , 2010, Shock.

[23]  L. Traber,et al.  Role of different nitric oxide synthase isoforms in a murine model of acute lung injury and sepsis. , 2010, Biochemical and biophysical research communications.

[24]  D. Herndon,et al.  Time course of nitric oxide synthases, nitrosative stress, and poly(ADP ribosylation) in an ovine sepsis model , 2010, Critical Care.

[25]  G. Fischer,et al.  Vasoplegia during cardiac surgery: current concepts and management. , 2010, Seminars in thoracic and cardiovascular surgery.

[26]  D. Herndon,et al.  CARDIOVASCULAR COLLAPSE AND VASCULAR PERMEABILITY CHANGES IN AN OVINE MODEL OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS SEPSIS , 2009, Shock.

[27]  L. Cribbs,et al.  Vascular KCNQ Potassium Channels as Novel Targets for the Control of Mesenteric Artery Constriction by Vasopressin, Based on Studies in Single Cells, Pressurized Arteries, and in Vivo Measurements of Mesenteric Vascular Resistance , 2008, Journal of Pharmacology and Experimental Therapeutics.

[28]  D. Herndon,et al.  NOVEL OVINE MODEL OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS-INDUCED PNEUMONIA AND SEPSIS , 2007, Shock.

[29]  K. Henderson,et al.  Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. , 2007, Journal of applied physiology.

[30]  D. Herndon,et al.  THE INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE IN OVINE SEPSIS MODEL , 2006, Shock.

[31]  M. Leone,et al.  Decreased vasopressin responsiveness in vasodilatory septic shock–like conditions* , 2006, Critical care medicine.

[32]  Djillali Annane,et al.  Septic shock , 2005, The Lancet.

[33]  J. Bakker,et al.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.

[34]  J. le Gall,et al.  Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)* , 2004, Critical care medicine.

[35]  M. Dünser,et al.  Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors* , 2003, Critical care medicine.

[36]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[37]  Karim Bendjelid,et al.  Fluid responsiveness in mechanically ventilated patients: a review of indices used in intensive care , 2003, Intensive Care Medicine.

[38]  G. Musch,et al.  Changes in regional ventilation after autologous blood clot pulmonary embolism. , 2002, Anesthesiology.

[39]  Corinne Alberti,et al.  Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study , 2002, Intensive Care Medicine.

[40]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[41]  D. Prough,et al.  Peroxynitrite Reduces Vasodilatory Responses to Reduced Intravascular Pressure, Calcitonin Gene-Related Peptide, and Cromakalim in Isolated Middle Cerebral Arteries , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  R. Balk,et al.  SEVERE SEPSIS AND SEPTIC SHOCK , 2000 .

[43]  T. Lincoln,et al.  Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha. , 1999, Science.

[44]  R F Woolson,et al.  The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Crapo,et al.  The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock , 1997, British journal of pharmacology.

[46]  J. Cobb,et al.  Nitric oxide and septic shock. , 1996, JAMA.

[47]  P. Dorinsky,et al.  Mechanisms of multiple nonpulmonary organ failure in ARDS. , 1989, Chest.

[48]  M. McCarron,et al.  Septic Shock , 1964, International anesthesiology clinics.

[49]  T. Grandin,et al.  AVMA Guidelines for the Euthanasia of Animals: 2013 Edition , 2013 .

[50]  D. Annane,et al.  Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis , 2011, Intensive Care Medicine.

[51]  D. Traber,et al.  Role of nitric oxide in shock: the large animal perspective. , 2009, Frontiers in bioscience.